Eli Lilly and Comp. Stock Buy or Sell? LLY Stocks Forecast

Market Capitalization: 717 353 320 000 $
EBITDA: 11 844 866 000 $
Price to Earnings: 136.89
Quarterly Earnings Growth YOY: 0.131
Quarterly Revenue Growth YOY: 0.281
Trailing PE: 136.89
Forward PE: 59.88
Shares Outstanding: 949307000

Trading Penny Stocks for Profit: Expert Insights and Practical Advice

February 22, 2024 Trading Penny Stocks for Profit: Expert Insights and Practical Advice

For aspiring traders and seasoned investors alike, the enticing appeal of penny stocks can be likened to voyaging across the vast oceans, discovering…
Getting A Kredittkort Norge Approval Isn’t Difficult

February 8, 2024 Getting A Kredittkort Norge Approval Isn’t Difficult

If you meet the conditions, you can open an account for checking in Norway. However, it will be much easier and more convenient…
How to Understand Social Security: 6 Legal & Financial Tips

January 25, 2024 How to Understand Social Security: 6 Legal & Financial Tips

Understanding social security can seem overwhelming, but it’s an important part of financial planning, particularly for retirement. The following 6 legal and financial…
Finding Energy Plans with Billig Strøm Rates

January 10, 2024 Finding Energy Plans with Billig Strøm Rates

It can be overwhelming to decide on the best plan when in a state where electricity is deregulated. The number of providers is…

Eli Lilly and Comp. Stock Buy or Sell? LLY Stocks Analytic Forecasts

Updated on February 27, 2024 (10:19)

Eli Lilly and Company (LLY prediction charts) Sector: Healthcare

We present you the most up-to-date and complete review of analytical trend forecasts and views on the LLY stock market. Experts share their opinions on what to expect from the Eli Lilly and Company stock market. How likely is the stock price to move in a bullish or bearish trend. Which should help you to make the right decision whether to Buy or Sell Eli Lilly and Comp. stocks.

Eli Lilly and Company Stock Market Experts’ Analysis and Forecasting – Sell or Buy LLY Shares?

The most recent analytical view which can help you to answer the worrying question: Should I Buy Stocks Now or Wait? came out under the authorship of Pedro Goulart and is titled

“Eli Lilly: Very Strong Fundamentals, But Market Is Euphoric”

is published on February 15 (2024) and has 0 likes. The review predicts Neutral market trend.

It summarize the following theses:

  • Eli Lilly’s financial results for Q4 2023 showed a 28% increase in total revenue compared to the same period last year.
  • The company’s new launch, Zepbound, is expected to drive sales growth in 2024 and contribute to a projected revenue growth of 18-22%.
  • Eli Lilly’s gross margin and net margin indicate a potential durable competitive advantage compared to its peers in the healthcare sector.

The author starts his analytic review with the following:

My Thesis My investment thesis and outlook for Eli Lilly (NYSE:LLY) is based on the dissonance between quantitative valuation metrics and the current share price. The growth expected by the market by analysts is also not properly parameterized for the stock. This takes us into a highly speculative zone.

The expert’s Followers level is low yet – less 100, but that will probably change soon.

Pedro Goulart is the contributor of experts community since 2024 and has 2 works published for the moment.

One more noteworthy article is written by Dair Sansyzbayev under the title

“Eli Lilly: Overvaluation Is A Big Red Flag”

on February 13 (2024) and has 1 likes. The expert reflects Bearish trend of the market.

Нis theses make you think about whether to add LLY stocks to your investment portfolio or not, and helps to work out your own Eli Lilly and Comp. stock selling strategies:

  • Eli Lilly’s stock is overvalued by around 27% despite its success in developing drugs for diabetes and obesity.
  • LLY has strong financial performance with steady revenue growth and profitability expansion.
  • The success of its drugs Mounjaro and Zepbound has led to a boost in revenue and positive growth prospects, but competition and market risks remain.

Dair Sansyzbayev starts analysis with such words:

Investment thesis Eli Lilly’s (NYSE:LLY) stock is on fire after the massive success of its new drugs aimed at treating diabetes and obesity. The company has a stellar track record of success and will likely continue delivering strong results over the long term. However, my valuation analysis suggests that the stock is around 27% overvalued, a premium I am not ready to pay even for a superstar like Eli Lilly. I believe that once the FOMO effect diminishes, buying opportunities closer to the stock’s fair price will likely emerge. Despite recognizing the company’s strength and strategic positioning, I view the current overvaluation as providing favorable selling opportunities. Therefore, I assign LLY a tactical “Sell” rating.

The opinion of the author can be considered quite authoritative.
The number of 4825 followers confirms this.
Dair Sansyzbayev is the contributor of experts community since 2023. Has already published at least 338 articles.

Another analysis presented by Bill Gunderson came out on February 8 (2024). Obviously, coupled with the newer reviews, this forecasting could be useful to find out the best trading strategy for LLY stocks. It sounds like

“Will Eli Lilly and Company Become A Trillion-Dollar Baby?”

Article has got 2 likes at the moment and forecasting Strong Bullish trend of the market.

Summarizing the information presented in the review concerning the Eli Lilly and Company, the expert says the following:

  • Eli Lilly and Company stock has seen a 21.8% increase since the article was written, outperforming the S&P 500.
  • The company’s strong earnings growth and potential for blockbuster drugs contribute to its continued success.
  • The 5-year target price for Eli Lilly has been raised to $1,318, indicating 81.8% upside potential over the next 3-5 years.

And here, what comes first:

I last wrote about Eli Lilly and Company (NYSE:LLY) back in a September 11, 2023 article. At that time, the stock was trading at $595.56 per share. I gave the stock a buy rating and put out a 5-year target price of $1,020 per share. During my 25 years as a professional money manager and analyst, I have always used 5-year target prices. It helps take a lot of short-term emotion out of the equation. In addition to this, why do analysts come up with 5-year growth rates and 6-month target prices? That makes no sense to me.

This author is very popular among the auditory. He has 21543 followers.

Bill Gunderson is the contributor of experts community since 2011 and has at least 389 analytic reviews published.

The Share Price of Eli Lilly and Company (LLY) for now

What analysts predict: $760.37
52-week high/low: $794.47 / $306.63

50/200 Day Moving Average: $636.18 / $546.36

The average stock price over the previous 50/200 days. For Eli Lilly and Comp. stocks, the 50-day moving average is the resistance level for now. For LLY stocks, the 200-day moving average is the resistance level today.

See the Detailed Predictions for LLY stock with charts and tables

Related Analysis

View all analytics

Buy or Sell ADGI shares?
January 1, 1970

Thermo Fisher’s Bright Future Makes It A Great Buy On Weakness

Buy or Sell TMO shares? Thermo Fisher’s Bright Future Makes It A Great Buy On Weakness
February 6, 2024
Drug manufacturers are facing a massive patent cliff, with over $200 billion in annual revenue at risk through 2030, meaning innovation is critical to prop up sales, and today's company focuses on that.

Revisiting Zynerba Pharmaceuticals

Buy or Sell ZYNE shares? Revisiting Zynerba Pharmaceuticals
November 11, 2021
Today, we revisit a small developmental firm called Zynerba Pharmaceuticals.

Danaher: Better Positioned For The Future

Buy or Sell DHR shares? Danaher: Better Positioned For The Future
February 3, 2024
Danaher's annual results show a decrease in sales and EBIT due to the boost in sales of the COVID-19 pandemic.